Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hypoxanthine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP known ✓ | P00491 | 1/20 | 0.55 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.46 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.45 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.43 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 known ✓ | P08238 | 1/20 | 0.42 |
| ▸ | PRKCD known ✓ | Q05655 | 1/20 | 0.42 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.95 |
| ▸ | PI4KA | P42356 | 2/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hypoxanthine SCHEMBL25381 | 0.97 | ALDH1A1 (1.00) | ALDH1A1PNPPI4KAPI4K2BPI4K2A | |
| Hypoxanthine SCHEMBL7037918 | 0.97 | ALDH1A1 (1.00) | ALDH1A1PNPPI4KAPI4K2BPI4K2A | |
| Hypoxanthine SCHEMBL30096461 | 0.97 | ALDH1A1 (1.00) | ALDH1A1PNPPI4KAPI4K2BPI4K2A | |
| Hypoxanthine SCHEMBL122843 | 0.95 | ALDH1A1 (0.95) | ALDH1A1PNPPI4KAPI4K2BPI4K2A | |
| Hypoxanthine SCHEMBL30703487 | 0.95 | ALDH1A1 (0.95) | ALDH1A1PNPPI4KAPI4K2BPI4K2A | |
| Hypoxanthine SCHEMBL29515776 | 0.95 | ALDH1A1 (0.95) | ALDH1A1PNPPI4KAPI4K2BPI4K2A | |
| Hypoxanthine SCHEMBL7168422 | 0.95 | ALDH1A1 (0.95) | ALDH1A1PNPPI4KAPI4K2BPI4K2A | |
| Hypoxanthine SCHEMBL2639254 | 0.95 | ALDH1A1 (0.95) | ALDH1A1PNPPI4KAPI4K2BPI4K2A | |
| Hypoxanthine SCHEMBL30605050 | 0.95 | ALDH1A1 (0.95) | ALDH1A1PNPPI4KAPI4K2BPI4K2A | |
| Hypoxanthine SCHEMBL28386541 | 0.95 | ALDH1A1 (0.95) | ALDH1A1PNPPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850216-B2 | 18F labeling of proteins using sortases | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-12-26 | — | — | US | disclosed |
| US-11787844-B2 | Targeting of chondroitin sulfate glycans | VAR2 PHARMACEUTICALS APS (DK) | 2023-10-17 | — | — | US | disclosed |
| CN-104136041-B | Targeted chondroitin sulfate glycans | VAR2制药有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20200384137-A1 | 18F LABELING OF PROTEINS USING SORTASES | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2020-12-10 | — | — | US | disclosed |
| CN-111410669-A | Method for preparing D-ribose and base | 上海艾美晶生物科技有限公司 | 2020-07-14 | — | — | CN | disclosed |
| US-10556024-B2 | 18F labeling of proteins using sortases | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2020-02-11 | — | — | US | disclosed |
| EP-2812024-B1 | TARGETING OF CHONDROITIN SULFATE GLYCANS | VAR2 PHARMACEUTICALS APS (DK) | 2018-04-11 | — | — | EP | disclosed |
| US-9932375-B2 | Targeting of chondroitin sulfate glycans | VAR2 PHARMACEUTICALS APS (DK) | 2018-04-03 | — | — | US | disclosed |
| US-9926350-B2 | Targeting of chondroitin sulfate glycans | VAR2 PHARMACEUTICALS APS (DK) | 2018-03-27 | — | — | US | disclosed |
| US-20170081373-A1 | TARGETING OF CHONDROITIN SULFATE GLYCANS | VAR2 PHARMACEUTICAL APS (DK) | 2017-03-23 | — | — | US | disclosed |
| WO-2003099789-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHACHALCOGENMETHYLCARBONYL COMPOUNDS | ERRANT GENE THERAPEUTICS, LLC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099272-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETOEPOXIDE COMPOUNDS | ERRANT GENE THERAPEUTICS, LLC (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099760-A1 | HISTONE DEACETYLASE INHIBITORS BASED ON TRIHALOMETHYLCARBONYL COMPOUNDS | ERRANT GENE THERAPEUTICS, LLC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030125306-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | CIRCAGEN PHARMACEUTICAL, A MARYLAND CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-6495719-B2 | FOR USE IN THERAPY OF CANCER, HEMATOLOGICAL DISORDERS, SUCH AS HEMATOPOIESIS, AND GENETIC RELATED METABOLIC DISORDERS, SUCH AS, CYSTIC FIBROSIS AND ADRENOLEUKODYSTROPHY | CIRCAGEN PHARMACEUTICAL | 2002-12-17 | — | — | US | disclosed |
| US-20020143196-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2002-10-03 | — | — | US | disclosed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850216-B2 | 18F labeling of proteins using sortases | SORT1, ANPEP, SPG11 | PNP 1080/4885DRD3 2815/4885ACHE 4349/4885 |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | ZFX, HDAC5, ZNF277 | PNP 3048/4885DRD3 4318/4885ACHE 4862/4885 |
| US-20020143052-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | PNP 3765/4885DRD3 4320/4885ACHE 4559/4885 |
| US-20030125306-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | PNP 3765/4885DRD3 4320/4885ACHE 4559/4885 |
| US-20020143196-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC5 | PNP 4274/4885DRD3 4506/4885ACHE 4837/4885 |
| US-20020143037-A1 | Histone deacetylase inhibitors | HDAC1, HDAC9, HDAC11 | PNP 3478/4885DRD3 4189/4885ACHE 4321/4885 |
| US-20200384137-A1 | 18F LABELING OF PROTEINS USING SORTASES | SORT1, ANPEP, SPG11 | PNP 1080/4885DRD3 2815/4885ACHE 4349/4885 |
| US-10556024-B2 | 18F labeling of proteins using sortases | SORT1, ANPEP, SPG11 | PNP 1148/4885DRD3 2734/4885ACHE 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.